Viridian Therapeutics, Inc.

Viridian Therapeutics develops drugs for rare diseases, particularly eye diseases related to thyroid problems. The company is working on treatments using monoclonal antibodies, which are proteins designed to target and block specific molecules in the body that cause disease. Two of their main drugs in development are Veligrotrug, given by injection into the vein, and Elegrobart, given under the skin less frequently. They are also developing treatments for Graves' disease, another thyroid condition, and exploring other protein-based approaches to reduce harmful antibodies in the body.